Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Acumen Pharmaceuticals, Inc.

< Previous 1 2 Next >
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Present During International Conference on Alzheimer’s and Parkinson’s Diseases 2025 and American Academy of Neurology Annual Meeting
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer’s Disease Publication of the Company’s Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
From Acumen Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers ABOS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.